- Home
- NCV vs FENC Comparison
NCV vs FENC Comparison
Compare NCV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCV | FENC |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.7M | 430.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NCV | FENC |
|---|---|---|
| Price | $16.50 | $12.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 48.2K | ★ 248.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $200.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.46 | $5.65 |
| 52 Week High | $17.65 | $13.25 |
Technical Indicators
Market Signals| Indicator | NCV | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 59.89 |
| Support Level | $16.33 | $9.74 |
| Resistance Level | $16.67 | N/A |
| Average True Range (ATR) | 0.29 | 0.57 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 13.08 | 80.89 |
Price Performance
Historical ComparisonAbout NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.